Dr. Maria del mar Torres-perez

Recommended Articles

• Community-Acquired Pneumonia: Causes, Symptoms, and Management

  Community-acquired pneumonia (CAP) refers to pneumonia that develops in people with very less or no contact with any medical setting such as a hospital or clinic. Most of the time, the people who are infected with CAP are healthy individuals.Background of the DiseaseFour million cases...

• Recent Study Evaluates Venous Blood Clot Risk in Children with Cystic Fibrosis

  Children with cystic fibrosis may be at risk of developing what's called a venous thromboembolism. This is essentially a blood clot that forms in the deep veins of the body, most often in the lower legs. These clots can be extremely dangerous because they can dislodge and travel to vital organs,...

• Symbicort (Budesonide/Formoterol) Inhalation Aerosol

  What is Symbicort?Symbicort is a combination drug used for the management of asthma and chronic obstructive pulmonary disease (COPD) symptoms. The two active ingredients of Symbicort are budesonide and formoterol. This combination helps relax the airways and makes breathing easier.Budesonide can be...

• Can Asthma Develop in Adulthood?

  In the not-so-distant past, researchers believed that asthma was a condition that always developed during childhood, and one that merely worsened in later adulthood. That theory has since been proven wrong, as asthma has begun to affect problem-free individuals in their thirties and later adult...

• Pneumonia in an Immunocompromised Patient

  Pneumonia as a disease was once dreaded, since most of the cases would turn out to be fatal. This was many years ago, and with medical advances, times have changed. However, in some severe cases of pneumonia, especially in people with weakened immune systems, the disease can still be fatal. If the...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...